Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of dazodalibep in Sjögren's syndrome with moderate to severe systemic disease activity
MOH_2024-02-22_013273Phase 3Recruiting
- Sponsor
- Horizon Therapeutics
- Start
- Nov 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dazodalibep in Sjögren's syndrome (3 arms), sponsored by Horizon Therapeutics. Primary endpoint: Primary efficacy endpoint. Started Nov 2023; status: recruiting.
02
Drugs
dazodalibep
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on MOH_2024-02-22_013273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-22_013273.